KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) Invested Capital (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Invested Capital for 11 consecutive years, with $1.9 billion as the latest value for Q4 2025.

  • Quarterly Invested Capital fell 0.53% to $1.9 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.9 billion through Dec 2025, down 0.53% year-over-year, with the annual reading at $1.9 billion for FY2025, 0.53% down from the prior year.
  • Invested Capital hit $1.9 billion in Q4 2025 for CRISPR Therapeutics AG, roughly flat from $1.9 billion in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $2.6 billion in Q2 2021 to a low of $1.7 billion in Q2 2025.
  • Historically, Invested Capital has averaged $2.0 billion across 5 years, with a median of $1.9 billion in 2024.
  • Biggest five-year swings in Invested Capital: surged 185.92% in 2021 and later decreased 22.24% in 2022.
  • Year by year, Invested Capital stood at $2.4 billion in 2021, then dropped by 21.84% to $1.9 billion in 2022, then grew by 0.39% to $1.9 billion in 2023, then grew by 2.62% to $1.9 billion in 2024, then decreased by 0.53% to $1.9 billion in 2025.
  • Business Quant data shows Invested Capital for CRSP at $1.9 billion in Q4 2025, $1.9 billion in Q3 2025, and $1.7 billion in Q2 2025.